Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : eDrugstores: Drugstore.com, PlanetRx and Soma -- Ignore unavailable to you. Want to Upgrade?

To: Firenze who wrote (102)	6/22/1999 6:41:00 PM
From: Tom D	Read Replies (1) \| Respond to of 254

It is good to have you around, Firenze. It is healthy to have somebody who can disagree with me without it degenerating into personal attacks--I need you to keep me honest. I don't know how I can investigate the matter of possible limitations with honoring deals with PCS at Drugstore.com further. It is a very important issue. It may have to wait until the next conference I attend, or something like that. Incidentally, BTW, I was wrong about Amaryl doing anything to lower insulin levels. I confused the fact that it lowers insulin requirements, which is an entirely different matter. Furthermore, do you have any evidence to support the idea that hepatotoxicity with Rezulin does not emerge if the patient makes it through the first 8-12 months without liver damage? The 3rd sentence in the boxed warning the the PI for Rezulin reads..."Injury has occurred after both short- and long-term troglitazone treatment." I had been interpreting this as to mean that it could show up anytime. Did you see in the Avandia PI where the FDA let them put in guidelines for switching patients from Rezulin over to Avandia? I find that rather remarkable. Best Regards, Tom D